A Weil team led by Private Funds partners James Sargent, Peter Boulle and Sophie Smith and Tax partners Aron Joy and Andrew Morris advised Gyrus Capital, a European investment firm dedicated to transformational investments in the healthcare and sustainability sectors, on the closing of a €600m single-asset continuation vehicle for Essential Pharma, an international specialty pharma group focused on ensuring that patients have access to low volume, clinically differentiated, niche pharmaceutical products across key therapeutic areas. The continuation vehicle was led by AlpInvest. Read more about this deal and view the full Weil team: https://lnkd.in/e2bNwPwQ
